Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
William R. Hiatt(University of Colorado Denver), Manesh R. Patel(Duke University), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Juuso Blomster(AstraZeneca (Netherlands)), Gretchen Heizer(Duke University), F. Gerry R. Fowkes(University of Edinburgh), Marcus Millegård(AstraZeneca (Netherlands)), Iris Baumgärtner(Hirslanden Klinik Beau-Site), Jeffrey S. Berger(New York University), Brian G. Katona(AstraZeneca (United States)), W. Schuyler Jones(Duke University), Peter Held(AstraZeneca (Netherlands)), Lars Norgren(Örebro University Hospital)
Cited by 628
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k